Axillary treatment of breast cancer patients is undergoing a paradigm shift, with the main question under scrutiny being how to treat the axilla of a patient with tumor-positive sentinel node biopsy (SNB). Since the introduction of SNB as a procedure to stage the axilla of breast cancer patients, the gold standard of treatment has been completion axillary lymph node dissection (ALND) for all cases with metastasis in the sentinel node (SN) or when the identification of SNs has failed.
Since then, many centers have developed their own predictive tools to identify patients with low risk of additional axillary metastases in whom completion ALND could be omitted (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . With a growing body of literature, many centers have abandoned completion ALND in patients with a low risk of nonsentinel node metastases (17) . The results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial further shook the completion ALND concept by showing that even a subset of patients with macrometastases in their SN do not benefit from completion ALND in terms of recurrence rate or overall survival (18, 19) .
Some centers have abandoned predictive tools altogether after the results of the ACOSOG Z0011 trial were published. However, vivid discussion continues on the generalization of the ACOSOG Z0011 results because the study only included patients who had undergone breast-conserving surgery followed by whole-breast radiation (18, 19) . Furthermore, contradicting results have been published recently, including the current analysis of the Dutch MIRROR cohort study, which showed an increased 5-year regional recurrence rate in patients with micrometastases in their SN and no completion ALND performed (20) .
Most of the current predictive tools estimating the likelihood of additional axillary metastases after tumor-positive SNB have been developed from single-institution patient series and thereafter validated in other centers. Current predictive tools have also been developed to identify patients with low risk of residual disease, rather than those with high risk, and tend to perform worse in a high-risk setting (21) .
In light of the ACOSOG Z0011 trial, this study aims to examine factors associated with a high risk of additional axillary metastases and to identify such high-risk patients for whom completion ALND might be warranted. This study further aims to develop a novel international and multi-institutional predictive tool to calculate a patient-specific risk of residual disease. Finally, we aim to validate the novel predictive tool first internally and then externally in various institutions.
Methods

Original Patient Series
Five European centers collected retrospective data, each on 200 consecutive women with invasive breast cancer with one or more tumorpositive SNs and a completion ALND, contributing a total of 1000 patients who were operated on between January 2004 and January 2011. Patients with macrometastasis, micrometastasis, or isolated tumor cells/clusters (ITC) in their SN were included. Patients who had neoadjuvant treatment or previous axillary surgery were excluded. These data were originally collected to assess the impact of differences in the SNB procedure and pathology practices on the performance of existing predictive models for nonsentinel node involvement (22) . Although the tools performed well in the institution in which they were developed, subsequent validation produced less-satisfactory and variable results. Hence, we decided to develop a novel predictive tool with emphasis on high-risk patients (22) .
The participating centers in the collection of this original patient series were Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Helsinki University Central Hospital, Finland; Medical University of Graz, Austria; Institute of Oncology, Ljubljana, Slovenia; and University of Szeged, Hungary.
The collected data were based on known risk factors for additional axillary metastases after tumor-positive SNB (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Primary tumor-specific variables included pathological tumor size, multifocality, histological and nuclear grade, histological type (ductal, lobular, mixed, or other), estrogen and progesterone receptor status, human epidermal growth factor receptor 2 (HER-2) status, and presence of lymphovascular invasion. Lymph node-specific variables included the number of tumor-positive and tumor-negative SNs and nonsentinel nodes, method of detection of the SN metastasis, size of the largest SN metastasis (ITC vs micrometastasis vs macrometastasis) (23) , and presence of extra-capsular extension of the SN metastasis. The method of detection of the SN metastases was categorized as intraoperative (frozen section/imprint cytology), paraffin standard staining, serial sectioning, or immunohistochemistry. Patient, tumor, and lymph node characteristics from different centers are given in Table 1 .
Surgical techniques and pathological work-ups of the primary tumors and the axillary specimen were conducted according to each center's protocols (22) .
Internal Validation Patients
Additional consecutive patients with similar inclusion and exclusion criteria to the original series were gathered from each center to form an internal validation series. The surgical treatment and methods of pathological assessment were similar to the original patient series. Data were collected on 500 additional patients who had surgery between 2003 and 2011.
External Validation Patients
Eight different centers, mainly from Europe but also from Japan, participated in the external validation of the predictive tool. Each external validation center provided consecutive patient series with similar inclusion criteria to the original series. The number of patients included from each center was not restricted because the performance of the predictive tool was examined separately in each center in addition to pooled performance. Altogether, 1068 patients were included in the external validation (Supplementary Data 1, available online) .
The participating centers in the collection of the external surgically treated validation patient series were Lariboisiere Hospital 
Statistical Analyses
A univariate analysis of the original patient series was conducted to examine individual risk factors for additional axillary metastases after tumor-positive SNB. Distribution of continuous variables (patient age, prevalence of nonsentinel node metastases in each center's patient series, histological size of the primary tumor, number of negative and positive SNs harvested) was analyzed using the Mann-Whitney U test, and the χ 2 test was used for categorical variables (multifocality of the primary tumor, lymphovascular invasion in the primary tumor, estrogen and progesterone receptor status, HER-2 status, nuclear and histological grade of the primary tumor, histology of the primary tumor, detection method of the SN metastasis, and extra-capsular extension of the SN metastasis). All statistical tests were two-sided with P values less than .05 considered significant.
All variables with a P value less than .1 in the univariate analysis were included in a logistic regression analysis using a backward stepwise likelihood ratio method. Variables with a P value less than .05 were included in the final predictive model.
The resulting multivariable predictive model was then validated both internally and externally by the independent patient series. Discrimination of the model was assessed by area under the receiver operating characteristic curve (AUC), and the calibration of the model was assessed by the Hosmer-Lemeshow goodness-offit test. Sensitivity and specificity of the model was determined for various cutoff values.
IBM SPSS Statistics version 20 (SPSS Inc., Chicago, IL) software was used to conduct the statistical analyses.
Ethical Considerations
The patient series were gathered retrospectively with no influence on patient therapy. Institutional review boards and ethical committees (12) 59 (11) 57 (13) 58 (10) 56 (11) Histological size of the primary tumor, mean (SD), mm 20 (14) 21 (18) 18 (9) 22 (11) 22 ( Nonsentinel nodes harvested, mean (SD), no.
12 (5) 19 (6) 15 (6) 17 (6) 10 ( at University hospital on November 2, 2012
http://jnci.oxfordjournals.org/ were consulted in each center as required, and no ethical objections were raised. All patient information was gathered anonymously.
Results
In the original patient series, 327 (32.7%) patients were found to have additional axillary metastases in their completion ALND. This proportion varied between centers from 27% to 40%. Variables associated with additional metastases in univariate analysis with a P value less than .1 were prevalence of nonsentinel node metastases in each center's series, size of primary tumor, multifocality, lymphovascular invasion, HER-2 status, histological and nuclear grade, SN metastatasis detection method, SN metastasis size, extracapsular extension of the SN metastasis, and number of tumor-negative and -positive SNs ( Table 2) . Prevalence of nonsentinel node metastases in each center's series, primary tumor diameter, multifocality, lymphovascular invasion, HER-2 status, SN metastasis size, extracapsular extension of the SN metastasis, and number of tumor-negative and -positive SNs remained statistically significant risk factors in the logistic regression analysis (Table 3 ). The Hosmer-Lemeshow test produced a P value of .58, indicating that the multivariable model fits and calibrates well for the patient population. The AUC for the original patient series was 0.756 (95% confidence interval [CI] = 0.725 to 0.787), suggesting good discrimination. The following mathematical model was produced from the logistic regression analysis to predict the presence of additional axillary metastases, with p denoting the probability of nonsentinel node metastases: Each patient's information from the internal and external validation patient series was then introduced into the multivariable equation to perform validation of the predictive model. AUC values with confidence intervals for each center are given in Table 4 , and receiver operating characteristic curves are given in Figure 1 . The prevalence of nonsentinel node metastases ranged from 20.8% to 36.0% between centers in the internal validation series and from 30.2% to 53.0% in the external validation series. Similarly, the AUC values ranged from 0.458 to 0.841 in the internal validation series between different centers and from 0.577 to 0.949 in the different external validation centers. Overall, internal validation of the predictive model yielded an AUC of 0.714 (95% CI = 0.665 to 0.763), whereas the external validation AUC was 0.719 (95% CI = 0.689 to 0.750) ( Table 4) .
The model generates a probability of additional metastases, which can be termed a risk estimate score, and the sensitivity and specificity of the predictive model may be calculated for any given cutoff value of the risk estimate score. For example, when applied to the external validation series, our model has a sensitivity of 67.6% and a specificity of 65.8% for a cutoff value of more than 50% of the risk score. The sensitivity and specificity of the model in the external validation series for different cutoff values are: greater than 10% risk (98.2% sensitivity and 7.5% specificity), greater than 20% risk (89.4% sensitivity and 31.6% specificity), greater than 30% risk (83.1% sensitivity and 43.9% specificity), greater than 40% risk (70.3% sensitivity and 61.6% specificity), greater than 60% risk (27.3% sensitivity and 91.4% specificity) and greater than 70% risk (12.4% sensitivity and 97.2% specificity).
Calibration of the predictive model was examined by grouping patients in each series into quintiles according to the predicted probabilities of additional metastases. A calibration plot was acquired by plotting the mean predicted probability of each quintile against the actual proportion of patients with additional metastases in each quintile ( Figure 2 ).
Discussion
Our predictive model is presented in the form of a multivariable equation that produces the probability of additional axillary metastases. Most of the previous models were given in the form of scores or nomograms that were always approximations of the original mathematical model (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In the contemporary era, we feel that the predictive equation is the most appropriate form because it produces the most accurate prediction and can be easily incorporated into various platforms, including computers and mobile devices. Moreover, by producing a probability of additional metastases, our predictive model is not tied into specific cutoff points because the thresholds for clinical decision making may well change in the future and increasingly become more patient specific.
The present model performed relatively well both in the internal and external validation. In fact, the model performed equally or even better in the external patient series than it did in the internal setup in terms of AUC. Furthermore, the model performed well in both low-risk (up to 10% risk) and high-risk (60% risk and over) conditions, as illustrated by the calibration plot (Figure 2 ). Other predictive models may not calibrate equally well, as shown by previous validation studies (15, 24) . In fact, we have recently validated four previous nomograms with the original patient series of this study with resulting AUC values of 0.640 to 0.686 and relatively poor performance in high-risk (>50% risk) settings (21) .
The baseline prevalence of additional axillary metastases in our original patient series (32.7%) is substantially lower than that of the external validation series (42.2%). Such baseline differences may be relatively customary and may account for poor performance of previous predictive tools in other centers. In fact, our model is the first predictive tool to incorporate each center's baseline prevalence of nonsentinel node metastases as a coefficient in the equation to calibrate the model.
The exclusion criteria for this study were intentionally minimal to produce a heterogeneous patient population closely resembling real-life patient material. Furthermore, the methodology of the preoperative nodal assessment, such as the use of axillary ultrasound, and the pathological nodal assessment varied considerably between centers, accounting for differences. A high-quality, preoperative, axillary ultrasound blocks a high proportion of women with macrometastases from the SNB procedure, thereby also lowering the proportion of women with additional nonsentinel node metastases. Differences between the centers both in internal and external validation are apparent, considering the variation of the AUC values in Table 4 . These may partly be due to small patient series from some centers, accounting for both very high (external validation Center J; AUC = 0.949) and very low (external validation Center H; AUC = 0.577) AUC values. These are most likely statistical variations that will be leveled with a higher number of patients. On the other hand, the alteration between centers may represent real methodological or population-wise differences, and further validation of the model with reasonably large patient series is of crucial importance before adoption into clinical use.
Although the present model produces simply the percentile probability of residual disease, the sensitivity and specificity of the model were tested, as an example, for a cutoff value of more than 50% risk score in Table 4 . In the wake of the ACOSOG Z0011 trial, such a high cutoff value was chosen because it is being substantially higher than those of previous models (1-16) and also considerably higher than the 27% risk of the ACOSOG patient series (18, 19) . Our model had a reasonably good sensitivity and specificity at this cutoff point, both in the internal and external validation series.
Nine variables were statistically significant in the logistic regression analysis and were incorporated into our predictive model. The prevalence of nonsentinel metastases is a center-or patient seriesspecific variable, which is a unique feature in the present model. Most of the other variables included in the model have been found to predict the risk for additional axillary metastases in previously published models (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , except for HER-2 status. HER-2 status stood out as an independent factor from estrogen and progesterone receptor status because both triple-negative and triple-positive combinations had similar distributions across the two groups in univariate analysis. The biological explanation behind this phenomenon remains unclear. The implications of HER-2 status on recurrences and survival have been extensively studied (25, 26) , but the detailed effects of steroid receptor and HER-2 status on axillary lymph node and especially nonsentinel node involvement have not been described in the literature. Triple-positive breast cancer has been shown to lead to highest incidence of tumor-positive lymph nodes in multivariable analysis (27) between different phenotypes, but this study did not find an association between nonsentinel node metastases and triple-negative or triple-positive phenotypes.
Our model includes SN metastasis size as a factor in the predictive equation. In fact, the distinction between ITC, micrometastasis, and macrometastasis as the SN finding greatly affects the probability of additional metastases. Some of the previous models do not take the SN metastasis size into consideration (1, 7, 11) , whereas some models are specifically designed for only ITC or micrometastases (9, 15, 16) .
The ACOSOG Z0011 trial suggested that omitting completion ALND after tumor-positive SNB does not increase regional recurrence rate nor decrease survival rate in general. The prevalence of additional axillary metastases was 27% on the ALND arm of the randomized ACOSOG trial, suggesting a comparable residual disease rate in the SNB-only arm. However, the study only included women having undergone breast-conserving surgery followed by whole-breast radiotherapy including the axilla through a tangential field. The prevalence of nonsentinel node metastases in our unselected patient series was considerably higher than in the ACOSOG trial (33% in our original series, 31% in the internal validation series, and 42% in the external validation series). A meta-analysis of more than 8000 patients reported an additional axillary metastases rate as high as 53% after a tumor-positive SNB (28) .
Many factors affect the baseline prevalence of axillary metastases in a given patient population. These include the method of preoperative nodal assessment and many primary tumor-specific factors, such as tumor diameter, which also determines whether a patient undergoes breast-conserving surgery or mastectomy. Therefore, the patient selection of the ACOSOG Z0011 trial may have led to a lower baseline prevalence of nonsentinel node metastases, and the results may not be generalizable to patients with a higher risk of additional metastases than the 27% reported in that study. Moreover, a substantial proportion of patients undergoing mastectomy do not receive radiotherapy and may be at a higher risk of regional recurrence than patients undergoing breast-conserving surgery and radiation (29, 30) . at University hospital on November 2, 2012 http://jnci.oxfordjournals.org/ Although most axillary recurrences have been reported to occur in the first 5 years after ALND (31), the metastatic tumor load to the axilla is believed to be considerably lower in the SNB era than in the period prior to it. Therefore, the presentation of recurrences may need a longer time than the 6.3 years of median followup reported to date (19) , despite the fact that at present there is not even a trend toward a decreased survival without completion ALND in the ACOSOG Z0011 trial.
The whole paradigm of axillary treatment of breast cancer patients is changing, but the future may well be multidirectional. In addition to completion ALND, axillary radiotherapy may also be a future option in the treatment of patients with tumor-positive SN. The European Organisation for Research and Treatment of Cancer AMAROS trial (32) is comparing axillary radiotherapy to completion ALND in a randomized set-up, but the final results have not yet been published. Patient-specific prediction of residual axillary disease may become even more relevant in the future because the treatment options of the axilla are under scrutiny. One implication of the ACOSOG Z0011 trial and also of the AMAROS trial is the diminishing role of intraoperative SN analysis and the adaptation of pathology methods to the clinical context (ie, to potential treatment options). Many previous predictive models include SN detection method or the use of frozen section analysis as a factor in the model. These models may become obsolete with possible abandoning of intraoperative SN analysis.
Our study also has limitations. The heterogeneity of our patient series probably reduces the performance of the predictive model in specific subgroups of patients. The subgroup of patients for whom predictive models are especially needed in the future is, however, unclear. Our novel predictive model may perform well in everyday practice with the average patient, but care needs to be taken in special cases with, for example, very large tumors or tumors representing rare histological types. Another limitation of this study is the variance in the patient enrollment times between different centers. This may have a negative impact on the performance of the new model.
We present a novel, international, multicenter, predictive tool to assess the risk of additional axillary metastases after tumorpositive SNB in breast cancer. In the era of changing paradigm, our tool seems to be able to also identify high-risk patients. The predictive model performs well in internal and external validation patient series, but on the basis of our previous results (21, 22) , it needs to be validated in each center before its application in clinical practice.
